Article

Data analysis confirms BPH as progressive disease

Results from a recent study that systematically analyzed the data of placebo-controlled trials in patients with BPH confirm that BPH is a progressive disease on the basis of worsening prostate volume, maximum urinary flow, and symptom score, as well as the rate of prostate-related surgery and acute urinary retention.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
Anna Myers, CNP, answers a question during a Zoom video interview
Related Content
Blur image of hospital corridor | Image Credit: © jakkapan - stock.adobe.com
April 27th 2025

Estimated DOR of 2 years is seen with UGN-102 in LG-IR-NMIBC

Benjamin P. Saylor
The investigators reported that the median Kaplan-Meier estimate of DOR was 24.2 months.
Pearls & Perspectives: Premature ejaculation, with Brian L. Steixner, MD
April 24th 2025

Pearls & Perspectives: Premature ejaculation, with Brian L. Steixner, MD

Amy M. Pearlman, MD Brian L. Steixner, MD
Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a board-certified urologist in Linwood, New Jersey.
Pablo Suarez, MS-4 | Credit: UCSF
April 26th 2025

Drinking water contaminants could increase risk of kidney stones, study finds

Patrick Campbell
New research links higher drinking water contaminants to increased kidney stone risk.
Introducing Pearls & Perspectives, with Amy Pearlman, MD!
April 21st 2025

Introducing Pearls & Perspectives, with Amy Pearlman, MD!

Amy M. Pearlman, MD
Pearls & Perspectives, hosted by Amy Pearlman, MD, is the latest multimedia program from Urology Times.
Nathan Lawrentschuk, MBBS, PhD | Credit: Epworth Healthcare
April 26th 2025

ADAM, a long-term, injectable male birth control, shows promise at AUA 2025

Patrick Campbell
A groundbreaking male contraceptive shows promising safety results, offering a reversible option for couples seeking effective birth control.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
April 26th 2025

ADVANCED-002: High CR rates observed with TARA-002 in high-grade NMIBC

Benjamin P. Saylor
Treatment with TARA-002 was associated with a 100% high-grade CR at any time in BCG-unresponsive participants.
© 2025 MJH Life Sciences

All rights reserved.